{
  "docId": "019de076-9434-73df-8e70-401e13bb3d65",
  "docSlug": "692690be0ea25b83b6a4c7490ff14999",
  "documentTitle": "BioAtla | Investor Presentation Deck | 55 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 55,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes comparative context to historical studies (pazopanib, pembrolizumab).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9434-73df-8e70-401e13bb3d65/25",
  "deckHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65",
  "deckJsonHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65.json",
  "deckAnchorHref": "/decks/019de076-9434-73df-8e70-401e13bb3d65#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.48,
        "w": 0.46,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Change Target Lesion From Baseline (%)",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fd60035-ef03-454e-b987-7a366e66a4ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.48,
        "w": 0.46,
        "x": 0.52,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Progression-free Survival",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "976f2205-f11c-4e10-8eb7-673823c84a45",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.46,
        "x": 0.03,
        "y": 0.78
      },
      "kind": "list",
      "text": "Combined Phase 1 & 2: efficacy evaluable = 10 TmPS ≥ 50%\n5 / 10 patients achieved PRs, with an ORR of 50% and PFS rate at 3 months of 60%\nResponses to BA3011 treatment are durable, with DOR currently exceeding 8 months\nInterim results satisfied the pre-defined Go criteria of UPS cohort into part 2 of the Phase 2 study\nAverage prior lines of systemic therapy = 3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34057422-47fe-4896-a493-5e9bb5a84d3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.46,
        "x": 0.51,
        "y": 0.78
      },
      "kind": "list",
      "text": "Phase 3 randomized study of pazopanib versus placebo in metastatic soft-tissue sarcoma (\"other\" cohort that included UPS), progressing despite previous chemotherapy, reported a median PFS of 4.6 months for pazopanib and 1.0 months for placebo.*\nSingle-arm SARC028 study of pembrolizumab in advanced UPS, reported median PFS of 3.0 months**\nLimitations of cross trial comparison should be taken into account when comparing studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f7f0918-fc28-47b4-a8fd-c26d5badbbc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Interim data- Data cut-off of Jan 18, 2023\n*Votrient package insert, accessed March 2023. **DOI: 10.1200/JCO.2019.37.15_suppl.11015 Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 11015-11015.\nTmPS, tumor membrane percent score; ORR, objective response rate; PFS, progression free survival; DOR, duration of response.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3316e326-d1bc-4e6a-b708-2b816498825d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Undifferentiated Pleomorphic Sarcoma (UPS): ORR 50%, Median PFS 10.9 months",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df5c5c63-0626-44b1-994a-46719182bf2c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Phase 1 & Phase 2, part 1 change in target lesion and progression free survival (1.8mg/kg; n=10)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73df428a-1807-4fd1-ab1d-6e1a9811c950",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 24,
      "beatId": "9bcd5a0a-740c-4853-97bc-75472d60fcdf",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Sizing",
      "beatSlug": null,
      "evidence": "Market sizing and potential opportunities are discussed on pages 24-29.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}